Purpose: To report clinical outcomes after pars plana endoscopic cyclophotocoagulation of the ciliary processes and pars plana (ECP-plus), a novel treatment for refractory glaucoma.
T here is no consensus on subsequent treatment steps in patients who have glaucoma that is refractory to multiple prior filtration or aqueous shunt surgeries and maximal medical therapy. 1,2 Additional tube shunt surgery or cyclodestructive procedures are management options in such cases. Traditional cyclodestructive procedures such as cyclocryotherapy and transscleral cyclophotocoagulation can reduce intraocular pressure (IOP) in this scenario, but they carry a significant risk of marked inflammation, hypotony and, to a lesser extent, phthisis. [3] [4] [5] [6] [7] [8] A more recent iteration of the cyclodestructive procedure is endoscopic cyclophotocoagulation (ECP). [9] [10] [11] The ECP instrumentation combines a diode endolaser, aiming beam, light source, and endoscope in a single probe. With ECP, laser can be delivered to the target tissue under direct visualization and at appropriately titrated energy levels, thereby minimizing collateral scleral and ciliary body stromal damage.
In standard "anterior ECP," the ciliary processes are photocoagulated by an anterior chamber approach, usually by clear corneal incisions. There are instances, however, in which IOP reduction by standard ECP is insufficient or anterior access to the ciliary processes is limited.
Here, we describe a novel surgical approach involving the standard photocoagulation of the ciliary processes and treatment of posterior ciliary processes and pars plana (ECP-plus) by a pars plana approach. We report clinical outcomes after this treatment in patients with refractory glaucoma in whom previous glaucoma filtration surgeries such as trabeculectomy and aqueous shunt surgery, and in some cases prior anterior ECP or transscleral cyclophotocoagulation, had failed to adequately lower IOP. To our knowledge neither this technique nor its efficacy and safety have been reported in the literature.
MATERIALS AND METHODS
A retrospective analysis was conducted of clinical data of study subjects consecutively visiting tertiary referral centers at the Doheny Eye Institute and University of Southern California, Los Angeles, CA, the UPMC Eye Center, University of Pittsburgh Medical Center, Pittsburgh, PA, and Retina Consultants, Little Silver, New Jersey. Institutional Review Board approval was obtained, and all research conformed to the tenets of the Declaration of Helsinki.
Inclusion criteria were a diagnosis of OAG or angleclosure glaucoma, insufficiently controlled IOP (IOP > 21 mm Hg) at least 3 months after the most recent glaucoma surgery, maximally tolerated medical therapy, and visual acuity of hand motions or better. Patients had failed prior glaucoma surgery such as trabeculectomy, aqueous shunt, transscleral cyclophotocoagulation, and anterior ECP. Exclusion criteria were light perception visual acuity or worse or evidence of tube blockage (eg, no plate bleb on slit-lamp biomicroscopy or B-scan ultrasound evaluation).
IOP was determined by Goldmann applanation tonometry by a trained certified ophthalmic technician. Baseline IOP was based on averaged measurements from 2 consecutive visits before surgery. Postoperative IOP was based on measurements at 1, 3, 6, 12, 18, and 24 months postoperatively.
The primary outcome was IOP, expressed as IOP level, magnitude of IOP reduction, and duration of IOP reduction. Secondary outcomes were the number of IOP-lowering medications needed postoperatively and presence of complications: hypotony (IOPr5 mm Hg on 2 consecutive visits), chronic hypotony (lasting more than 3 mo), severe uveitis associated with fibrin formation, corneal edema, hyphema, shallow anterior chamber, cystoid macular edema, corneal edema or graft failure, endophthalmitis, and retinal detachment.
Treatment success was defined as 5 mm HgrIOPr21 mm Hg and lowered greater than 20% from baseline. Conversely, subjects failed treatment if IOP > 21 mm Hg, IOP < 5 mm Hg on 2 consecutive follow-up visits after 1 month, IOP reduction was <20% below baseline, additional glaucoma surgery was needed, or there was loss of light perception vision.
Intervention
Three surgeons (B.A.F., R.N., M.U.) each performed about one-third of the ECP-plus procedures under monitored anesthesia care with intravenous sedation and retrobulbar anesthesia of approximately 3 mL of lidocaine 1% mixed with bupivicaine 0.5%. Cyclopentolate 1%, phenylephrine 2.5%, and mydriacil 2% were used for pupil dilation. Before ECP-plus, a standard 2-port or 3-port pars plana vitrectomy was performed. An anterior chamber maintainer was used with 2-port vitrectomy. The ECP probe was then inserted into the posterior segment through a pars plana sclerotomy while another port was plugged and irrigation maintained. The probe was advanced toward the pars plana region and adjacent ciliary processes and used to view this region endoscopically by an external monitor. Each ciliary process and the intervening space between processes was photocoagulated between a 300-degree and 330-degree circumference of the ciliary body. Laser settings were 250 to 350 mW in continuous surgeoncontrolled duration. The treatment endpoint was whitening and shrinkage of each process and the intervening ciliary epithelium.In addition, the anterior 1 to 2 mm of pars plana adjacent to the processes was lasered to the point of whitening (Fig. 1) . At the conclusion of the procedure, instruments were removed from the eye and vitrectomy ports were sutured closed. Perioperative medications included the surgeon's choice of the following: subconjunctival injection of 0.1 mL of dexamethasone 1%, intracameral injection of preservative-free dexamethasone 1% (400 to 500 mg), intravenous administration of steroids, and topical tobramycin-dexamethasone ointment.
In the immediate postoperative period, patients were instructed to continue their prior glaucoma medical treatment regimen, in addition to starting antibiotic drops 4 times daily, prednisolone acetate 1% every 1 to 2 hours while awake, and a topical nonsteroidal anti-inflammatory 2 to 3 times a day. Antibiotic drops were discontinued after 7 to 10 days. Steroid, anti-inflammatory and glaucoma medications were tapered as IOP and inflammation permitted. If there was significant postoperative intraocular inflammation, a tapering course of oral steroids (prednisone) was given.
Subjects were followed up after 1 day and 1 week, then at months 1, 3, 6, 12, 18, and 24 postoperatively. 
Statistical Analysis
Paired t test significance testing was used to compare preoperative IOP and IOP at different time-points postoperatively, and number of medications taken preoperativley and postoperatively. Kaplan-Meir survival analysis of the cumulative success of treatment was conducted and expressed as survival curves over time. Treatment failure was defined as above. Patients who failed were included in comparing means of groups but they were censored from the survival analysis for subsequent time-points in standard manner for Kaplan-Meier survival analysis.
RESULTS
Fifty-three subjects were included, with each subject contributing data from 1 eye. Treatment was performed over a 40-month period. If a subject underwent bilateral treatment, data from the first-treated eye was used in the study. The mean age ( ± SD) was 62.4 ( ± 19.5) years. Fifty of the 53 of subjects had 6 months', 28/53 had 12 months', and 10/53 had 24 months' follow-up, respectively.
The glaucoma diagnoses are shown in Table 1 , including 32.1% (17/53) with primary open-angle glaucoma, 26.4% (14/53) with chronic primary angle-closure glaucoma, and the rest (41.5%) with secondary OAG and various subtypes. Table 2 describes the number and type of prior surgeries, with special attention to prior glaucoma surgeries. Thirteen of the 53 subjects (25%) had undergone more than 1 aqueous tube shunt implantation, and 28/53 (53%) had undergone more than 1 trabeculectomy. Other prior glaucoma surgeries included transscleral cyclophotocoagulation (8%), ECP by an anterior approach (4%), trabectome (2%), and gold shunt implantation (2%).
The change in IOP over time is shown in Table 3 . Compared with the mean preoperative IOP of 27.9 ± 7.5 mm Hg (t = 0), there was a significant IOP reduction after ECPplus treatment at 1 to 6 months (10.2 ± 5.6), 12 months (10.7 ± 5.2), and 18 to 24 months (9.4 ± 5.8) (all P < 0.0001).
This represented a mean percentage IOP reduction compared with baseline of 61% at 1 to 6 months, 63% at 12 months, and 66% at 18 to 24 months. Individual IOP data preoperatively and at 3 to 6 months postoperatively are shown in Figure 2 , which includes data from 50/53 subjects. Figure 3 shows preoperative and last postoperative IOP data for all study subjects.
Glaucoma medications are reported in Table 4 , which shows that the mean ( ± SD) number of medications fell significantly from 3.5 ± 1.2 before ECP-plus treatment to 0.8 ± 1.0 at 1 to 6 months, 0.7 ± 1.2 at 12 months, and 0.7 ± 1.1 at 18 to 24 months (all P < 0.0001). Compared with the preoperative baseline, this represented a mean decrease in number of medications of 71% at 1 to 6 months, 73% at 12 months, and 77% at 18 to 24 months.
The Kaplan-Meier survival function tabulation is shown in Table 5 . Failure was defined as: (a) IOP > 21 mm Hg, (b) <20% IOP reduction below baseline, (c) IOP < 5 mm Hg on 2 consecutive follow-up visits after 1 month, (d) additional glaucoma surgery, or (e) loss of light perception vision. Using standard Kaplan-Meier protocol, the number at risk was the number at risk at previous follow-up minus those censored. The number censored equaled the number of failures at previous follow-up plus the number lost to follow-up at the current time-point.
By this definition, cumulative success at 1 month was 85%, and at 6 months it was 81% (total 10 failures), with a minimal number of subjects lost to follow-up at the 6-month mark (3/53, 6%). At 12 months, cumulative success was 78%, with 1 additional failure recorded (total 11 failures), although more subjects were lost to follow-up (13/53, 25%). At 24 months, cumulative success remained at 78%, although this was based on fewer remaining subjects (34/53 lost to follow-up). Figure 4 shows the Kaplan-Meier survival function after ECP-plus treatment based on a definition of success of IOP reduction to 5 mm HgrIOPr21 mm Hg, and lack of any of the following: (a) IOP < 5 mm Hg or IOP > 21 mm Hg on 2 consecutive visits after 1 month; (b) IOP-lowering of <20% relative to baseline; (c) additional glaucoma surgery; and (d) loss of light perception vision. The KaplanMeier analysis was performed for the initial 12-month postoperative period during which there was a relatively low drop-out rate, which was 3/53 (6%) at 6 months, and 13/53 (25%) at 12 months. Cumulative success was 81% at 6 months and 78% at 12 months. During the first 12 months, the highest number of failures was seen in the first month postoperatively (8/53, 15%). Otherwise within the first year, 1 subject failed the treatment in each subsequent 3-month period to 12 months.
Complications in the early postoperative period (< 3 mo) were as follows: 4/53 (8%) subjects had hypotony (IOP < 5 mm Hg), with 2/4 having serous choroidal detachments. A further 2/53 had shallow choroidal detachments despite IOPZ5 mm Hg, with the detachment in 1 subject resolving by the end of follow-up. Two of the 53 (4%) subjects had uveitis with anterior chamber fibrin formation. All initial uveitis resolved by 3 months postoperatively. Two of the 53 (4%) had hyphema, with this resolving in both within the initial 3-month postoperative period. Four of the 53 (6%) had cystoid macular edema without hypotony. Beyond 6 months postoperatively, 4/50 (8%) had hypotony, with 3/4 subjects having choroidal detachments. One subject had persistent choroidal detachment despite IOPZ5 mm Hg. Thus, total subjects with choroidal detachment were 4/50 (8%). Two of the 4 subjects with choroidal detachments required surgical drainage of the choroidal detachments. Two of the 4 subjects with chronic hypotony had preexisting diagnoses of neovascular or uveitic glaucoma. Three of the 50 (6%) had cystoid macular edema without hypotony (including 1 subject with choroidal detachment). One of the 50 (2%) subjects had a failed corneal graft requiring further grafting. One of the 50 (2%) required further IOP-lowering surgery. The remaining patients failed treatment not because of complications but because IOP lowering did not meet the criteria for treatment success.
Visual acuity in the early postoperative period (< 3 mo) improved or remained unchanged in 45/53 (85%) of subjects. Eight of the 53 (8%) subjects showed worsened acuity of 2 Snellen lines or more. Nine of the 50 (18%) subjects showed worsened visual acuity at 6 months, with worsened acuity in these patients attributable to the following: hypotony (4/50, 8%), cystoid macular edema without hypotony (3/50, 6%), failed corneal graft (1/50, 2%), and choroidal neovascularization from age-related macular degeneration (1/50, 2%). No subjects suffered retinal detachment, phthisis bulbi, or endophthalmitis.
DISCUSSION
ECP-plus treatment in patients whose glaucoma was uncontrolled by prior glaucoma surgeries and maximally tolerated medical therapy resulted in significant IOP lowering and reduction of glaucoma medications needed to control IOP. Our data show that the ECP-plus effect was sustained over at least 12 months. Our 2-year follow-up data, although less complete, also showed sustained IOP lowering with ECP-plus. The profile of vision-threatening complications from this treatment appeared to be acceptable in this group of patients with refractory glaucoma. ECP of the ciliary processes by an anterior chamber approach has been found to reduce IOP by approximately 30%. 2, [12] [13] [14] In eyes with prior aqueous shunts, ECP of 360 degrees of anterior ciliary processes reduced IOP by an average of 31%. 12 We found that ECP-plus treatment reduced IOP by 61% to 66%, a much greater reduction compared with reports of ECP by an anterior chamber approach. The ECP-plus treatment we report involved laser application to the anterior and posterior ciliary processes and pars plana by a pars plana approach. More than half our patients had received multiple prior glaucoma surgeries, which included trabeculectomy, aqueous shunt implantation, transscleral cyclophotocoagulation, anterior cyclophotocoagulation, trabectome, and suprachoroidal shunt implantation. It was, thus, difficult to judge if the extent of ECP-plus-induced pressure lowering was influenced by the type of prior glaucoma surgery.
Laser application to posterior ciliary processes but not pars plana by a pars plana approach have been reported. 9, 12, 15, 16 In 1 study, 17 IOP was controlled between 5 and 21 mm Hg for at least 12 months in 68% to 87% of 73 eyes in a group of patients with ocular comorbidities that included epithelial ingrowth and retinal detachment. Stable or improved visual acuity was seen in 73%. Complications developed in 12%; these included hypotony, choroidal effusion, fibrinous anterior chamber reaction, phthisis, choroidal hemorrhage, and corneal graft rejection. Our 6-month complication rate was 16% (8/50), including all cases of hypotony, choroidal detachment, corneal graft failure, and cystoid macular edema. All subjects with prior neovascular and uveitic glaucoma developed hypotony, and it is possible that our hypotony rate would have been higher if more subjects had these diagnoses.
In another study, 12 less extensive laser of the posterior ciliary processes (210 degrees compared with our application over 300 to 330 degrees) caused a mean IOP reduction of 37% at 12 months, and 34% at 24 months. The mean IOP at 24 months was 14.1 mm Hg, compared with our finding of 9.4 mm Hg at 12 months (10.7 mm Hg at 12 mo with more complete follow-up). The mean number of medications was reduced by 33%, compared with our finding of 77% (73% at 12 mo with more complete followup). The success of IOP control at 2 years was 74%, compared with our finding of 78% (12 and 24 mo). This suggests that extent of treatment of the ciliary processes beyond 210 degrees using the parameters we used produces additional IOP lowering and has therapeutic value. Our data and prior data agree that effective IOP control over at least 1 to 2 years is achievable by ECP by a pars plana approach.
Our ECP-plus treatment approach relied on photocoagulation of the anterior and posterior aspects of the ciliary processes and pars plana and was more extensive than that previously reported for ECP by pars plana or anterior chamber approaches. 2, [12] [13] [14] It is not surprising that ECP-plus induced more IOP lowering than these other approaches. Nevertheless, the complication profile of ECPplus treatment was similar to that of aggressive anterior ECP in complicated glaucomas. Complications of anterior ECP in these patients are reported as hypotony or choroidal effusion (4%), fibrinous uveitis (24%), hyphema (12%), and cystoid macular edema (10%). 14 Our early complications of ECP-plus were hypotony or serous choroidal detachment (8%), cystoid macular edema (6%), uveitis (4%), and hyphema (4%). Uveitis and hyphema resolved in the early postoperative period. Complications persisted in the late postoperative period (6 mo) in 8/50 (16%) subjects: hypotony or choroidal detachment (8%), cystoid macular edema (6%), and corneal graft failure (2%). Nine of the 50 (18%) subjects had worsened visual acuity at 6 months after ECP-plus, with age-related macular degeneration being a contributor. The rate of corneal graft failure after ECP-plus was similar to that reported for anterior ECP. 2 Possible explanations for the magnitude of IOP reduction with ECP-plus relate to treatment under direct visualization of: (a) the entire ciliary processes, (b) intervening regions between processes, (c) the pars plana, and (d) the extent of circumferential treatment. Pars plana treatment may have several effects. First, photocoagulation of any extension of the secretory ciliary epithelium from pars plicata onto pars plana results in more complete reduction of aqueous humor production. Second, a possible effect on the blood supply to the ciliary body would result in more profound aqueous suppression. Third, lasering the pars plana may increase uveoscleral outflow.
The main weaknesses of this study were its retrospective nature and inherent difficulties of ensuring uniform data collection in this multicenter study. We tried to control for variable time-points of IOP measurement and data collection by choosing time-points that were mostly common to the different centers. We attempted to reduce the bias of regression to the mean for IOP by averaging measurements before surgery. The number of patients lost to follow-up, especially beyond 12 months postoperatively, affected the extent to which we could conclusively judge the longevity of treatment effects at the later postoperative time-points of 18 and 24 months. Ninety-four percent and 75% of study subjects were retained at 6 and 12 months, respectively. Subjects remaining in the study gradually diminished thereafter so that 34/53 (64%) of subjects were lost to follow-up at 24 months. This largely reflected the nature of practices involved in this study, as many patients came for treatment as tertiary referrals. They would have returned to their referring doctors after having been stable for a reasonable period after treatment. Our Kaplan-Meier survival analysis, thus, appropriately focused on the first year postoperatively when more complete follow-up provided a robust representation of treatment outcomes. We combined this earlier more complete data with our entire dataset over 24 months in Table 5 . Analysis of the remaining patients beyond 12 months painted a picture similar to that seen in earlier follow-up in that IOP reduction remained relatively sustained after ECP-plus treatment. After treatment algorithms may have varied slightly between treatment centers, we feel that our findings reflect the realities of real-world medical care and are applicable to patients with refractory glaucoma seeking tertiary treatment in centers such as those represented here.
We have sought to characterize clinical outcomes of a novel approach for treating refractory glaucoma that we have called ECP-plus. This approach, using laser treatment applied to the ciliary processes and pars plana by a pars plana approach, lowers IOP effectively. Patients require fewer medications postoperatively. The magnitude of IOP lowering after ECP-plus is expected to be significant and to exceed that of anterior ECP. And yet the IOP lowering is achieved with a complication profile that is not dissimilar to that of the more widely used and accepted anterior ECP. Lower IOP seems achievable depending on the extent of circumferential treatment, although this is limited by the possibility of hypotony. We do not recommend treating 360 degrees, and we recommend caution in patients with diminished ciliary body function such as in neovascular or uveitic glaucoma. Our data indicate that IOP lowering is relatively sustained after ECP-plus treatment in eyes with refractory glaucoma in which maximally tolerated medical treatment and multiple glaucoma surgeries have failed to control IOP.
